Ipilimumab: A Novel Treatment for Metastatic Melanoma (Q37866936)

24 August 2017

1 reference

title

Ipilimumab: a novel treatment for metastatic melanoma (English)

1 reference

24 August 2017

Ipilimumab: A Novel Treatment for Metastatic Melanoma (English)

1 reference

30 November 2024

0 references

1 reference

Morgan E. Culver

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21505108

30 November 2024

Mandy L. Gatesman

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21505108

30 November 2024

Erin E. Mancl

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21505108

30 November 2024

Denise K. Lowe

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21505108

30 November 2024

language of work or name

English

0 references

publication date

19 April 2011

1 reference

full work available at URL

24 August 2017

http://www.theannals.com/cgi/content/abstract/45/4/510

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21505108

https://journals.sagepub.com/doi/pdf/10.1345/aph.1P651

30 November 2024

1 reference

Annals of Pharmacotherapy

30 November 2024

published in

1 reference

24 August 2017

1 reference

24 August 2017

1 reference

24 August 2017

page(s)

510-519

1 reference

Final version of 2009 AJCC melanoma staging and classification

24 August 2017

cites work

1 reference

Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study

21 January 2018

1 reference

Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines

21 January 2018

1 reference

The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma

21 January 2018

1 reference

Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes

21 January 2018

1 reference

Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient

21 January 2018

1 reference

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

21 January 2018

1 reference

CTLA-4: new insights into its biological function and use in tumor immunotherapy

21 January 2018

1 reference

CTLA-4 and tolerance: the biochemical point of view

21 January 2018

1 reference

Molecular basis of T cell inactivation by CTLA-4

21 January 2018

1 reference

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies

21 January 2018

1 reference

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

21 January 2018

1 reference

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

21 January 2018

1 reference

The role of the CTLA4 blockade in the treatment of malignant melanoma

21 January 2018

1 reference

Checkpoint blockade in cancer immunotherapy

21 January 2018

1 reference

Immunostimulatory monoclonal antibodies for cancer therapy

21 January 2018

1 reference

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment

21 January 2018

1 reference

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

21 January 2018

1 reference

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

Phase I/II study of ipilimumab for patients with metastatic melanoma

21 January 2018

1 reference

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).

21 January 2018

1 reference

Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

21 January 2018

1 reference

Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis

21 January 2018

1 reference

European Journal of Surgical Oncology

21 January 2018

175

Cascinelli N

1986

1 reference

Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma

30 November 2024

1 reference

Local and in-transit metastases following definitive excision for primary cutaneous malignant melanoma

30 November 2024

1 reference

Complete regression of a previously untreated melanoma brain metastasis with ipilimumab

30 November 2024

1 reference

30 November 2024

Identifiers

DOI

10.1345/APH.1P651

1 reference

24 August 2017

1 reference